Sugi Predict

Sugi Predict / Compounds / SCHEMBL1369562

SCHEMBL1369562

SCHEMBL1369562

CCN(Cc1ccccc1)c1ccc(-c2cccc(N3CCCS3(=O)=O)c2)nn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.40
▸ ENPP2 Q13822 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ PHGDH O43175 1/20 0.38
▸ CDK1 P06493 3/20 0.38
▸ CDK2 P24941 3/20 0.38
▸ CDK4 P11802 2/20 0.37
▸ PTK2 Q05397 1/20 0.37
▸ ADRB2 P07550 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ HTR1D P28221 1/20 0.37
▸ HTR1B P28222 1/20 0.37
▸ HTR1F P30939 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ HTR7 P34969 1/20 0.37
▸ ADRA1B P35368 1/20 0.37
▸ HTR5A P47898 1/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ HTR4 Q13639 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369219 0.74 ENPP2 (0.42) TP53ENPP2MAPTSMN1; SMN2
SCHEMBL1369566 0.74 POLB (0.38) TP53POLBPHGDHCDK1CDK2
SCHEMBL692966 0.71 NR3C1 (0.56) TP53POLBSMN1; SMN2
SCHEMBL692379 0.69 PRMT6 (0.43) TP53ENPP2POLBMAPTSMN1; SMN2
SCHEMBL3242528 0.68 ENPP2 (0.45) TP53ENPP2SMN1; SMN2
SCHEMBL7710033 0.68 ENPP2 (0.38) TP53ENPP2MAPTSMN1; SMN2
SCHEMBL692774 0.68 NR3C1 (0.44) TP53ENPP2POLBMAPT
SCHEMBL692541 0.67 NPC1 (0.53) TP53POLBMAPTSMN1; SMN2
SCHEMBL692595 0.65 TP53 (0.45) TP53POLBHTR6MAPT
SCHEMBL12209941 0.65 POLB (0.57) TP53POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US claimed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US claimed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 — — US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 TP53 1160/4885ENPP2 825/4885POLB 4046/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 TP53 3179/4885ENPP2 802/4885POLB 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.